Vernalis Launches Extended-Release Cough Relief Syrup
Tuzistra XR for cough relief is said to be the only twice-daily, extended-release codeine-based cough and cold syrup available in the US.
Vernalis and Tris Pharma announced that Tuzistra XR (codeine polistirex and chlorpheniramine polistirex), extended-release oral suspension, CIII (DEA Schedule III) is now available to patients and physicians in the United States.
FDA approved the extended-release formulation in April 2015 for the relief of cough, common cold, and symptoms associated with upper respiratory allergies in adults. Tuzistra XR is said to be the only codeine-based extended-release cough cold syrup available in the US.
The US cough cold prescription market has been valued at more than $3 billion, with 30–35 million annual prescriptions. This market is dominated by short-acting treatments, which require dosing four to six times a day.
Tuzistra XR was developed using Tris Pharma's liquid sustained release technology, LiquiXR, which allows for extended drug delivery throughout a 12-hour dosing period.
Source: Vernalis
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
